North Korea develops a vaccine against the Corona virus.
The Council for Scientific Research in Pyongyang said Saturday that its scientists are now conducting clinical trials to develop a vaccine against the virus.
A report issued by the North Korean government science and technology committee said that a medical biology institute under the leadership of the North Korean Academy of Medical Sciences is leading efforts to develop a vaccine, using what is known as "angiotensin-converting enzyme 2" or "ACE2".
This enzyme converts angiotensin 1 to angiotensin 2 and the function of angiotensin 2 is to absorb sodium.
North Korea stated that it had confirmed the immunity and safety of its vaccine, through animal tests, and that clinical trials had begun this month.
In line with this, the government has been collecting blood samples from fully recovered patients in several areas including Daegu, once the epicenter of the outbreak in the country.
Content created and supplied by: SetInformation (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More